tradmap

CLDI Earnings Calidi Biotherapeutics, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$36 -$16 $3 $0 2022 2023 2024 2025
EPS
Revenue (annual)
$0 $22500 $45000 2022 2023 2024 2025
Revenue
Net income (annual)
-$29M -$15M $0 2022 2023 2024 2025
Net income

Quarterly results

Diluted EPS (quarterly)
-$66 -$33 $0 Q3 '22 Q2 '23 Q1 '24 Q3 '24 Q2 '25 Q1 '26
EPS
Net income (quarterly)
-$8M -$4M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income
Return on equity (quarterly)
-324% -69% 185% 0% Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
ROE

Reported EPS history

1–16 of 16
Q2 20262026-06-30-8.312026-08-1310-Q
Q1 20262026-03-31-0.432026-05-1410-Q
FY 20252025-12-31-5.952026-03-2710-K
Q3 20252025-09-30-6.402025-11-1310-Q
Q2 20262025-06-30-66.472026-08-1310-Q
Q1 20262025-03-31-2.212026-05-1410-Q
FY 20252024-12-31-35.702026-03-2710-K
Q3 20252024-09-30-42.402025-11-1310-Q
Q2 20252024-06-30-39.612025-08-0810-Q
Q1 20252024-03-31-2.032025-05-1410-Q
FY 20242023-12-31-17.332025-03-3110-K
Q3 20242023-09-30-19.802024-11-1210-Q
Q2 20242023-06-30-21.752024-08-1310-Q
Q1 20242023-03-31-0.752024-05-1410-Q
FY 20232022-12-312.992024-03-1510-K
Q3 20232022-09-30-2.082023-11-1410-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.